The Parkview Mirro Center for Research and Innovation Initiates Study to Demonstrate Value of Personalized Patient Engagement for Those Suffering from Heart Failure
Patient Engagement Strategies Have the Potential to Encourage Self-Care that Improves Quality of Life
FORT WAYNE, Ind., May 5, 2016 /PRNewswire/ -- The Parkview Mirro Center for Research and Innovation and Parkview Physicians Group (PPG)-Cardiology today announced the initiation of the interventional study Engaging Patients in Heart Failure Management. The study, funded through a research grant from BIOTRONIK, Inc., is designed to demonstrate the impact of remote monitoring and personalized patient engagement as a means to empower congestive heart failure patients who have a cardiac resynchronization therapy cardiac implantable electronic device (CRT-CIED) to overcome barriers to seek necessary medical care.
According to the Centers for Disease Control and Prevention, nearly 5.1 million people in the United States have heart failure. Approximately half of the people who develop heart failure die within five years. Determining personalized patient engagement strategies that provide near real-time health information has the potential to encourage self-care that guides patients to the hospital or clinic for necessary adjustments to their medical therapy.
The Engaging Patients in Heart Failure Management study will explore the implications of sending CRT-CIED device data and alerts through patient personal health records (PHR). Currently, important CRT-CIED recorded data is buried in the patient's electronic health record (EHR) and only seen by health care providers. The study seeks to demonstrate that sending personalized messages to CRT patients with specific left ventricular (LV) pacing details and related alerts from CIED remote monitoring will result in: 1) improved patient engagement; 2) an increased awareness of when to call the clinic for changes in therapy; 3) an improved percentage of LV pacing over six months compared to historical controls from the same clinic.
"This study will demonstrate the tremendous value of patient engagement in treating heart failure patients," said Dr. Michael Mirro, Medical Director, Parkview Research Center and co-principal investigator of the study. "Consistent, reliable remote monitoring data from the BIOTRONIK CIEDs provides the unique opportunity to help patients and caregivers become more involved in care. Heart failure patients often struggle with other chronic conditions, making it difficult to know when it is necessary to seek care. We want to create a more preventative care model that enables patients to take a proactive role in their own healthcare. This study will further prove the critical role of remote monitoring and patient engagement in improving clinical outcomes."
The Engaging Patients in Heart Failure Management study will be conducted in three phases. In the recently completed first phase, the investigators employed a user-centered design approach to better understand what types of information patients who have a remote-monitored BIOTRONIK CRT-CIED would find beneficial in understanding and managing their disease. The second phase of the study, currently in progress, involves implementing the PHR intervention as designed in phase one. In the third phase of this study, the investigators will test the PHR intervention in a single arm, six-month trial. All patients enrolled in the study have previously received a BIOTRONIK CRT-CIED that provides home monitoring capabilities. BIOTRONIK Home Monitoring transmits patient heart data automatically on a daily basis, thereby rapidly detecting deterioration in a patient's clinical status. The study is expected to be completed in December 2017.
About the Parkview Mirro Center for Research and Innovation
The Parkview Mirro Center for Research and Innovation has adopted a bold mission to provide opportunities that will open new doors and potentially revolutionize healthcare to save lives. This mission is an extension of the commitment that Parkview Health has made to the communities it serves throughout northeast Indiana, northwest Ohio and south-central Michigan. Individuals and families, healthcare providers and innovators will be better equipped to face the future as a result of the powerful vision, clinical expertise and medical investigation that takes place at the Mirro Center. The Parkview Research Center is currently conducting more than 105 clinical trials with work spanning cardiovascular science, neuroscience, oncology and health informatics. Parkview Health is the region's largest healthcare provider, serving a population of more than 820,000.
Photo - http://photos.prnewswire.com/prnh/20160505/364300
SOURCE The Parkview Mirro Center for Research and Innovation
Share this article